Company: PFSA
Filing Date: 2025-05-09
Form Type: S-4/A
Source: 0001213900-25-041151
Chunk: 263

Company: Profusa, Inc.
Filing Date: 2025-05-09
Form: S-4/A
Chunk 263
---
 Profusa’s management. Included in the term sheets were sources & uses of funds, pro forma cap tables, estimated fees and earnouts provisions based on various post -closestock price trading. •On June2, 2022, NorthView presented Profusa with an initial draft of a non -exclusiveletter of intent (“LOI”). •On June8, 2022, NorthView management presented the detailed terms of the two non -exclusiveletters of intent for Company A and Profusa to the NorthView Board of Directors who approved signing both letter of intent in substantially the form presented. •From June 2 through June12, 2022, there were various calls, meetings, discussions and negotiations related to the key terms of the letters of intent. The Profusa LOI, which valued Profusa at $155 million, was finalized on June10, 2022 and subsequently executed on June13, 2022, with an effective date of June10, 2022. The parties held an update call with representatives of Profusa management, NorthView management, HCW and I -BankersSecurities on or about June15, 2022. •In addition to the Profusa LOI, NorthView entered into a second non -exclusiveletter of intent with Company A, effective as of June10, 2022. •On June16, 2022, Tungsten initiated a weekly update call including the CEO of Company A, representatives of I -Bankers, two representatives of Tungsten and NorthView management. •On June23, 2022, a list of updated documents in the Profusa virtual data room was presented to NorthView. The virtual data room was populated with, among other things, documents relating to Profusa’s organizational structure, governing documents, historical financial statements and material contracts. The NorthView team and its legal representatives at ArentFox Schiff LLP continued to conduct diligence on Profusa’s business including its financial outlook, product roadmap, patent strategy, technology platform, and clinical programs and progress, as well as pending product approvals, marketing channels, investor agreements and growth initiatives. •On June24, 2022, Profusa provided Northview with the Initial Projections. The Initial Projections were prepared solely by management of Profusa. See “ Opinion of Marshall & Stevens — Initial Financial Projections” for more information. •On June29, 2022, an internal evaluation was made by the NorthView team which identified Profusa as its lead target candidate for a business